Forte Biosciences (37T) Price & Analysis

0 Followers

37T Stock Chart & Stats

€26.40

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€26.40

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€8.10 - €43.20

Previous CloseN/A

Volume0.00

Average Volume (3M)3.00

Market Cap

€876.53M

Enterprise Value€403.77

Total Cash (Recent Filing)€58.22M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 17, 2026

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.58

Shares Outstanding20,478,817

10 Day Avg. Volume1

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)65.81

Price to Sales (P/S)0.00

P/FCF Ratio-78.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€58.57

Price Target Upside121.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-3.6

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Capital StructureZero reported debt meaningfully lowers financial risk and interest burden, preserving cash for R&D. For a clinical-stage biotech, a debt-free structure increases strategic optionality for partnering or milestone financing and reduces fixed financing costs over the medium term.

Positive Phase 1b Vitiligo DataRobust, placebo-controlled Phase 1b efficacy and favorable safety materially de-risk FB102's clinical profile. Durable signals and early onset of benefit improve the program's attractiveness to partners, support expansion into autoimmune indications, and strengthen the company's long-term clinical thesis.

Governance And Incentive AlignmentRe-election of directors, auditor ratification, and an updated equity plan reinforce board continuity, external oversight, and management retention. Strong governance and aligned incentives sustain multi-year program execution and improve credibility with investors and potential collaborators.

Bears Say

No Revenue; Widening LossesAbsence of operating revenue and materially widening net losses indicate the company is R&D-funded rather than self-sustaining. Persistent unprofitability forces reliance on external capital, increasing dilution risk and constraining the company's ability to independently advance multiple late-stage programs.

Deep Negative Cash Flow / Cash BurnSustained negative operating and free cash flow with sizeable TTM burn reduces runway and forces prioritization of programs. Dependence on financings can delay trials or change development timelines and raises execution risk if capital markets tighten over the medium term.

Declining Equity And AssetsEroding equity and shrinking assets reflect cumulative cash depletion from losses, weakening the balance sheet. This reduces borrowing capacity and bargaining leverage in partnerships, shortening the time window before additional capital is required and constraining strategic flexibility.

Forte Biosciences News

Forte Biosciences initiated with an Overweight at Barclays

Barclays initiated coverage of Forte Biosciences (FBRX) with an Overweight rating and $74 price target The firm views...

6h ago

FBRX

Why Is Forte Biosciences (FBRX) Stock Up Today?

Forte Biosciences stock was up on Friday alongside positive results from a clinical trial. ...

11d ago

FBRX

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $44 from...

11d ago

FBRX

TRAX

Midday Fly By: PepsiCo reports mixed Q2, Levi Strauss posts ‘beat and raise’

The major averages were broadly higher in a reversal of yesterday’s losses, with stock futures moving modestly higher...

12d ago

ASX

AZN

Forte Biosciences trading resumes

09:42 EDT Forte Biosciences (FBRX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

12d ago

FBRX

Forte Biosciences trading halted, volatility trading pause

09:32 EDT Forte Biosciences (FBRX) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

12d ago

FBRX

Forte Biosciences’ FB102 shows efficacy in vitiligo Phase 1b study

Forte Biosciences (FBRX) announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved...

12d ago

FBRX

Forte Biosciences Reports Positive Phase 1b Vitiligo Results

The latest announcement is out from Forte Biosciences ( ($FBRX) ). On July 9, 2026, Forte Biosciences reported...

12d ago

FBRX

Forte Biosciences Shareholders Approve Directors and Governance Items

Forte Biosciences ( ($FBRX) ) just unveiled an announcement. At its 2026 annual meeting of stockholders held on...

2M ago

FBRX

Forte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts

TD Cowen analyst Yaron Werber has maintained their bullish stance on FBRX stock, giving a Buy rating on...

2M ago

FBRX

Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)

“FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s...

2M ago

FBRX

Forte Biosciences Prices $150 Million Public Offering

Forte Biosciences ( ($FBRX) ) has issued an announcement. On April 8, 2026, Forte Biosciences, Inc. priced a...

3M ago

FBRX

Forte Biosciences 5.71M share Spot Secondary priced at $26.27

The deal size was increased to $150M and priced at the closing price. Guggenheim is acting as sole...

3M ago

FBRX

Forte Biosciences announces common stock offering, no amount given

Forte Biosciences (FBRX) announced that it has commenced an underwritten public offering of shares of its common stock....

3M ago

FBRX

37T FAQ

What was Forte Biosciences Inc.’s price range in the past 12 months?

Forte Biosciences Inc. lowest stock price was €8.10 and its highest was €43.20 in the past 12 months.

What is Forte Biosciences Inc.’s market cap?

Forte Biosciences Inc.’s market cap is €876.53M.

When is Forte Biosciences Inc.’s upcoming earnings report date?

Forte Biosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 27 days.

How were Forte Biosciences Inc.’s earnings last quarter?

Forte Biosciences Inc. released its earnings results on May 11, 2026. The company reported -€1.086 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Forte Biosciences Inc. overvalued?

According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Forte Biosciences Inc. pay dividends?

Forte Biosciences Inc. does not currently pay dividends.

What is Forte Biosciences Inc.’s EPS estimate?

Forte Biosciences Inc.’s EPS estimate is -0.81.

How many shares outstanding does Forte Biosciences Inc. have?

Forte Biosciences Inc. has 20,478,817 shares outstanding.

What happened to Forte Biosciences Inc.’s price movement after its last earnings report?

Forte Biosciences Inc. reported an EPS of -€1.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.182%.

Which hedge fund is a major shareholder of Forte Biosciences Inc.?

Currently, no hedge funds are holding shares in DE:37T

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Forte Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

41.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Forte Biosciences Inc.

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Forte Biosciences (37T) Earnings & Revenues

Historic Earnings Reports

37T Stock 12 Month Forecast

Average Price Target

€58.57

▲(121.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","66":"€66","21.75":"€21.8","36.5":"€36.5","51.25":"€51.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65.557836,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€65.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.56500015999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.32037328,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€53.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,21.75,36.5,51.25,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.4,22.027525846153843,25.65505169230769,29.28257753846154,32.91010338461538,36.53762923076923,40.16515507692307,43.79268092307692,47.42020676923077,51.04773261538461,54.675258461538455,58.302784307692306,61.93031015384615,{"y":65.557836,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.4,21.489615396923075,24.57923079384615,27.66884619076923,30.758461587692302,33.84807698461538,36.937692381538454,40.027307778461534,43.11692317538461,46.206538572307686,49.29615396923076,52.38576936615384,55.47538476307692,{"y":58.56500015999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.4,21.086182559999997,23.772365119999996,26.45854768,29.144730239999998,31.830912799999997,34.51709536,37.20327792,39.88946048,42.575643039999996,45.261825599999995,47.94800816,50.63419072,{"y":53.32037328,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >